Cargando…

Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus

BACKGROUND: Cancer stem cells/initiating cells (CSC/CIC), are thought to exist as a small population in malignant tissues. They are resistant to conventional cancer treatments and possibly underlie post-treatment relapse. The CIC population can be targeted with capsid modified oncolytic adenoviruses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahtiainen, Laura, Mirantes, Cristina, Jahkola, Tiina, Escutenaire, Sophie, Diaconu, Iulia, Österlund, Pamela, Kanerva, Anna, Cerullo, Vincenzo, Hemminki, Akseli
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2974645/ https://www.ncbi.nlm.nih.gov/pubmed/21079774 http://dx.doi.org/10.1371/journal.pone.0013859

Ejemplares similares

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

SPECT/CT Imaging of hNIS -Expression after Intravenous Delivery of an Oncolytic Adenovirus and (131)I
por: Rajecki, Maria, et al.
Publicado: (2012)

Fc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatment
por: Hirvinen, Mari, et al.
Publicado: (2013)

Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5
por: Ahonen, Marko T., et al.
Publicado: (2010)

Mutation of the Fiber Shaft Heparan Sulphate Binding Site of a 5/3 Chimeric Adenovirus Reduces Liver Tropism
por: Koski, Anniina, et al.
Publicado: (2013)

Analysis of predictive and prognostic factors in 290 patients treated with oncolytic adenoviruses
por: Taipale, Kristian, et al.
Publicado: (2015)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

Adenoviruses with an α(v)β integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastases
por: Lavilla-Alonso, Sergio, et al.
Publicado: (2010)

Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy
por: Farzad, Lisa, et al.
Publicado: (2014)

Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses
por: Kanerva, Anna, et al.
Publicado: (2008)

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
por: Heiniö, Camilla, et al.
Publicado: (2020)

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021)

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
por: Havunen, Riikka, et al.
Publicado: (2018)

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer
por: Liikanen, Ilkka, et al.
Publicado: (2022)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

Oncolytic Adenoviruses for Cancer Therapy
por: Tripodi, Lorella, et al.
Publicado: (2021)

Oncolytic Immunotherapy: Where Are We Clinically?
por: Hemminki, Akseli
Publicado: (2014)

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
por: Havunen, Riikka, et al.
Publicado: (2016)

Toxicological and bio-distribution profile of a GM-CSF-expressing, double-targeted, chimeric oncolytic adenovirus ONCOS-102 – Support for clinical studies on advanced cancer treatment
por: Kuryk, Lukasz, et al.
Publicado: (2017)

MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver
por: Ylösmäki, Erkko, et al.
Publicado: (2013)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2018)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
por: Quixabeira, Dafne C. A., et al.
Publicado: (2021)

Portrait of a Leader in Immunotherapeutics: Oncolytic viruses for treatment of cancer
por: Hemminki, Akseli
Publicado: (2012)

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting
por: Clubb, James H. A., et al.
Publicado: (2023)

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
por: Quixabeira, Dafne C. A., et al.
Publicado: (2022)

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
por: Kudling, Tatiana V., et al.
Publicado: (2022)

Innate immune defects in HIV permissive cell lines
por: Rausell, Antonio, et al.
Publicado: (2016)

Optimized Mouse Model for the Imaging of Tumor Metastasis upon Experimental Therapy
por: Lavilla-Alonso, Sergio, et al.
Publicado: (2011)

Serotype Chimeric Human Adenoviruses for Cancer Gene Therapy
por: Ranki, Tuuli, et al.
Publicado: (2010)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
por: Basnet, Saru, et al.
Publicado: (2022)

Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus
por: Callegari, Elisa, et al.
Publicado: (2013)

Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance
por: Tähtinen, Siri, et al.
Publicado: (2015)

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients
por: Taipale, Kristian, et al.
Publicado: (2018)

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment
por: Hemminki, Kari, et al.
Publicado: (2022)

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
por: Havunen, Riikka, et al.
Publicado: (2021)

Oncolytic adenoviruses coated with MHC-I tumor epitopes for a new oncolytic vaccine platform
por: Capasso, Cristian, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v7ioiqgj7e0pok8niui4c182dh